This course has expired. You can still review the content but course credit is no longer available.
Supported through an educational grant by Alimera Sciences.
Upon completion of this activity, the participant should be able to:
•Describe the current epidemiology of diabetic macular edema and diabetic retinopathy
•Educate patients on the ophthalmic implications of systemic diabetes management
•Assess clinical studies involving new approaches to treat DME
•Use expert case examples to differentiate between clinical study dosing protocols and alternative dosing schedules
•Evaluate treatment options and develop a treatment regimen that can reduce patient burden and practice capacity
•Explain the early warning signs of elevated IOP
•Identify effective management strategies for patients requiring intervention
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education and Retina Today.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an educational grant from Alimera Sciences.
Diabetes mellitus (“diabetes”) is a growing worldwide epidemic, affecting largely a working age population. By 2035, it is estimated close to 600 million people worldwide will be living with diabetes, a marked increase from the 382 million in 2013. Patients with diabetes are at an increased risk of several morbid and chronic conditions, among them acute coronary syndrome, hypertension, and retinopathy.
Pravin U. Dugel, MD
Retinal Consultants of Arizona
Baruch D. Kupperman, MD, PhD
UC Irvine Health Gavin
Herbert Eye Institute
The following faculty members have the following financial relationships with commercial interests:
Pravin U. Dugel, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/ Advisory Board: Abbott Medical Optics; Aerpio Therapeutics: Alcon; Alimera Sciences; Allergan; Annidis; Acucela; ArticAx US Ltd.; Avalanche Biotechnologies; Clearside Biomedical; DigiSight; DOSE Medical; Genentech; Lutronic; Lux BioSciences; Novartis; OD-OS; Omeros; Ophthotech; Opthea Limited; Optuvue; ORA; Regeneron Pharmaceuticals; Roche Pharma; PentaVision LLC; Stealth BioTherapeutics; ThromboGenics; and Topcon Corporation. Stock Shareholder: Alimera Sciences; Aerpio Therapeutics; Annidis; DigiSight; Neurotech USA; Ophthotech; and TruVision.
Baruch D. Kuppermann, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/ Advisory Board: Aerpio Therapeutics; Alcon; Alimera Sciences; Allergan; Allegro Ophthalmics, LLC; Ampio Pharmaceuticals; DOSE Medical; Eleven Biotherapeutics; Genentech; GlaxoSmithKline; Glauxos Corporation; Lumenis; Neurotech Pharmaceuticals; Novartis; Ophthotech Corporation; Regeneron Pharmaceuticals; SecondSight Medical Products; and ThromboGenics. Grant/ Research Support: Alcon; Alimera Sciences; Allergan; Allegro Ophthalmics LLC; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Genentech; GlaxoSmithKline; Neurotech Pharmaceuticals; Ophthotech Corporation; Regeneron Pharmaceuticals; and ThromboGenics.